Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Department of Spine Surgery, Xi'an Jiaotong University, Xi'an, China.
Curr Med Chem. 2021;28(25):5201-5212. doi: 10.2174/0929867328666201222125225.
Tuberculosis, caused by Mycobacterium tuberculosis, is one of the oldest diseases in the world and is one of the top ten causes of death in the world, ranking first mortality in infectious diseases, far beyond the frightening disease AIDS. Besides that, spinal tuberculosis is the most common form of extrapulmonary tuberculosis, accounting for approximately 1 to 3% of all tuberculosis cases, and accounting for 50% of musculoskeletal infections. However, the drug-resistant situation of spinal tuberculosis is still challenging world wide. This situation directly leads that spinal tuberculosis has a high disability rate and is difficult to treat, which causes a heavy burden to patients, families and society. Therefore, it has been one of the focuses of tuberculosis researchers and spine doctors. Considering that, in this review, we aim to overview the current studies that focused on the novel understanding of current spinal tuberculosis medicine usage and extensive explorations for treating this severe disease.
结核病是由结核分枝杆菌引起的，是世界上最古老的疾病之一，也是世界十大死因之一，在传染病中死亡率排名第一，远远超过令人恐惧的艾滋病。此外，脊柱结核是最常见的肺外结核形式，约占所有结核病病例的 1%至 3%，占肌肉骨骼感染的 50%。然而，脊柱结核的耐药情况仍然是全世界面临的挑战。这种情况直接导致脊柱结核的残疾率很高，难以治疗，给患者、家庭和社会带来沉重负担。因此，它一直是结核病研究人员和脊柱医生关注的焦点之一。有鉴于此，在本综述中，我们旨在概述当前针对脊柱结核药物使用的新认识，并对治疗这种严重疾病进行广泛探索。
